Columbus joins national fight accusing drug manufacturers of inflating insulin prices
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
cweb12h
Eli Lilly: Dominating the Diabesity Market with Long-Term Growth Potential
BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...
Baltimore City school system sues drug companies over allegedly inflated price of insulin
The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Josh Gottheimer
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...
Rep. Josh Gottheimer Sells Eli Lilly and Company (NYSE:LLY) Stock
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...